Namir Hassan
Company: Zelluna Immunotherapy
Job title: CEO
Seminars:
TCR-NK: A Unique Approach to Allogeneic Off the Shelf Cell Therapy Treatment of Solid Cancers 2:30 pm
The TCR-NK platform: bringing the solid tumor targeting benefits of TCRs and the highly potent off-the shelf killing mechanism of NK cells Developing a pipeline of TCR-NK products against well-validated TCR antigensRead more
day: Day One
Industry Leaders Fireside Chat – What Does the Future Hold for TCR therapies? 10:00 am
The hotly anticipated Industry Leader’s Fireside Chat will discuss the huge progress being made in the TCR therapeutic space. This session will explore the lessons we can takes from CAR-T, and will shed clarity on the priorities of the trailblazing companies in this field, whilst also touching upon the challenges faced with manufacturing costs, and…Read more
day: Day One
Chair’s Opening Remark 9:25 am
day: Day One